Clinical trials for psilocybin and other research in cancer
Learn about the foundational clinical trials and newer research exploring the power of psilocybin for cancer patients.Psilocybin research FOCUSED ON CANCER in the early 2000’s The first FDA-approved study for psilocybin with advanced-stage cancer patients was granted to Dr. Charles Grob at UCLA. This was a pilot study limited to 12 patients, to test the safety and feasibility of psilocybin. Participants received a smaller dose than previous studies (0.2 mg/kg patient weight), and the control received a non-psychoactive compound (niacin). This phase 1 study was a pioneering step in the use of psychedelic-assisted therapy to treat the psychological distress of patients with late-stage cancer.“Although past researchers reported more pronounced therapeutic effects with a higher-dose model, even the lower dose of psilocybin used in the current study gave some indication of therapeutic benefit in quantitative psychological evaluations.”
Landmark Trials involving psychedelics in cancer: 2010’s breakthroughs Two separate trials conducted by Johns Hopkins University and NYU Langone Health, published in 2016, are widely recognized as the most important studies in the use of psilocybin for alleviating the psychological, emotional, and existential distress for cancer patients.Recruitment for the 2016 Johns Hopkins psilocybin study began around 2014, focusing on cancer patients experiencing significant anxiety or depression due to their diagnoses. The FDA-approved study upheld rigorous safety and ethical standards throughout the research. The study included 51 participants and was designed as a double-blind, randomized, placebo-controlled trial. Participants received either a high dose of psilocybin or a placebo (a small dose of psilocybin), with the sessions guided by trained facilitators to ensure safety and support.
- About 80% of participants showed clinically significant decreases in depression and anxiety six months post-treatment, with around 60% achieving symptom remission.
- About 80% of participants rated the experience to be among the top 5 most personally and spiritually significant of their lives.
- Approximately 60–80% of participants showed sustained improvement in anxiety and depression, with a similar range for symptom remission at the six-month mark.
- “I am not afraid of death”
- “Choosing to live now”
- “There is a natural flow of life—I am part of that flow”
- “Death is a natural part of life, and it need not be feared”
- “Less anxiety about my body and my sickness coming back”
- “Connectedness and unity with the universe and cosmos”
- “I was everything... I was all this—this was me”
- “One therapeutic function of psilocybin may be to assist participants in achieving insight into the cause of their distress, which is supplemented by our supportive and integrative psychotherapy treatment model” (from the
NYU follow-on study) - “My team and I hypothesize that psychedelic sessions might have an advantage over traditional prescription antidepressants for patients with cancer-related depression or anxiety because it may help them deal with their underlying trauma” (from the
University of Connecticut study)
For a great summary presentation about the numerous Johns Hopkins studies of psilocybin for cancer, you can hear from Dr. Roland Griffiths in his
You can read the results of the
Watch
You can also read
The information on this site is for educational purposes only and is not intended as medical advice. Psychedelics may or may not be legal in your jurisdiction. Consult a lawyer if you have questions about the law, and consult your care team before making any decisions about your health. Legal notice.
Note: There are several psychedelics under investigation for treatment of the mental and emotional symptoms of cancer. While we focus almost exclusively on psilocybin, we will include breaking information from trusted sources about others (MDMA, Ketamine, etc.).